New Jersey Medicaid and tirzepatide
New Jersey Medicaid did not cover GLP-1s for weight loss as of January 2026, according to KFF, though it must cover them for type 2 diabetes.
In 2025 New Jersey Medicaid paid for 44,265 tirzepatide prescriptions (Mounjaro, Zepbound), 27% of its GLP-1 prescriptions and 15th of the 50 states and DC. It reimbursed $46.8 million before rebates, $1,056 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 37,880 | $39.9 million | $1,054 |
| Zepbound | 6,385 | $6.8 million | $1,071 |
New Jersey plans and prescribing rules
New Jersey State Health Benefits Program (SHBP). New Jersey's State Health Benefits Program covers Wegovy, Saxenda and Zepbound for weight loss in 2026, at a $45 copay for a 30-day retail supply or $135 for a 90-day mail-order supply.
Tirzepatide in the states around New Jersey
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| New Jersey | 17 | $69/moWellmedr | 44,265 | Medicaid Zepbound: Not covered (KFF) |
| Delaware | 17 | $69/moWellmedr | 15,771 | Medicaid Zepbound: Unclear |
| New York | 17 | $69/moWellmedr | 218,875 | Medicaid Zepbound: No |
| Pennsylvania | 17 | $69/moWellmedr | 243,243 | Medicaid Zepbound: No |



